Healthcare / Medical - PharmaceuticalsUpdated 2026-05-10 22:07 UTC

LON/0JBU stock hub

LON/0JBU has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

LON/0JBUis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.4B

London Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

LON/0JBU

In the news

Latest news · LON/0JBU

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.9P50 16.9P75 23.5

Trailing P/En/a

P25 15.9P50 22.9P75 35.8

ROE-53.5

P25 -54.2P50 2.1P75 13.7

ROIC-29.8

P25 -38.1P50 3.3P75 11.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All LON/0JBU market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

167

Groups with data

Currency

USD

Showing 167 of 167 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	UK
Employees	377
Employees Change	-123%
Employees Change Percent	-23.38
Enterprise value	$1.1B
Exchange	London Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Medical - Pharmaceuticals
Isin	US45826J1051
Last refreshed	2026-05-10
Market cap	$1.4B
Price	$14.02
Price currency	USD
Rev Per Employee	133,367.51x
Sector	Healthcare
Sic	2836
Symbol	lon/0JBU
Website	https://www.intelliatx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-21.22%
EV Earnings	-3.49x
EV/FCF	-3.64x
EV/Sales	21.53x
FCF yield	-20.36%
P/B ratio	2.9x
P/S ratio	28.73x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-190.8M
Net Income	$-306.6M
Net Income Growth Quarters	3%
Net Income Growth Years	1%
Pretax Margin	-609.85%
Profit Per Employee	$-813,347
ROA	-27.11
Roa5y	-22.82
ROCE	-59.74
ROE	-53.48
Roe5y	-45.09
ROIC	-29.85

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	92.01%
Cagr3y	-31.99%
Cagr5y	-27.75%
EPS Growth Quarters	6
EPS Growth Years	3
Revenue Growth	16.92x
Revenue Growth Q	78.79x
Revenue Growth Quarters	3x
Revenue Growth Years	2x
Revenue Growth3 Y	9.09x
Revenue Growth5 Y	3.13x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.07
Assets	$625.7M
Cash	$334.3M
Current Assets	$387.1M
Current Liabilities	$76.2M
Debt	$69.3M
Debt Equity	$0.14
Debt FCF	$-0.24
Equity	$498.8M
Liabilities	$126.9M
Long Term Assets	$238.6M
Long Term Liabilities	$50.7M
Net Cash	$380.3M
Net Cash By Market Cap	$26.32
Net Cash Growth	-21.45%
Net Debt Equity	$-0.76
Tangible Book Value	$498.8M
Tangible Book Value Per Share	$4.29
WACC	14.2

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	5.08
Net Working Capital	$314,289
Quick ratio	4.42
Working Capital	$314.9M
Working Capital Turnover	$0.11

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-9.64%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	91.92%
200-day SMA	13.2
3Y total return	-68.55%
50-day SMA	13.68
50-day SMA vs 200-day SMA	50over200
5Y total return	-80.31%
All Time High	200.8
All Time High Change	-93.02%
All Time High Date	2021-06-30
All Time Low	5.95
All Time Low Change	135.83%
All Time Low Date	2025-04-07
ATR	1.28
Beta	1.93
Ch YTD	54.05
High	14.54
High52	28.33
High52 Date	2025-10-21
High52ch	-50.51%
Low	13.72
Low52	6.83
Low52 Date	2025-05-30
Low52ch	105.24%
Ma50ch	2.52%
Price vs 200-day SMA	6.22%
RSI	51.15
RSI Monthly	45.25
RSI Weekly	53.63
Sharpe ratio	0.99x
Sortino ratio	1.45
Total Return	-9.64%
Tr YTD	54.04
Tr1m	4.86%
Tr1w	6.17%
Tr3m	15.49%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	$-327.7M
Operating margin	-651.7

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	134,155,947%
Shares Insiders	1.33%
Shares Institutions	73.57%
Shares Qo Q	5.2%
Shares Yo Y	9.64%
Short Ratio	7.92

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-353.7M
Average Volume	43,460.85x
Bv Per Share	4.29
CAPEX	$-838,847
Ch1m	4.86
Ch1w	6.17
Ch1y	91.92
Ch3m	15.49
Ch3y	-68.55
Ch5y	-80.31
Ch6m	55.45
Change	3.09%
Change From Open	2.19
Close	13.6
Days Gap	0.88
Depreciation Amortization	7,164,231.2
Dollar Volume	541,508.5
Earnings Date	2026-05-14
EBIT	$-327.7M
EBITDA	$-320.4M
EPS	$-2.83
F Score	3
FCF	$-294.1M
FCF EV Yield	-27.51x
Financing CF	97,694,098
Fiscal Year End	December
Founded	2,014
Investing CF	169,427,033
Is Primary Listing	0
Last Earnings Date	2026-02-26
Last Report Date	2025-12-31
Ma150	13.43
Ma150ch	4.42%
Ma20	14.23
Ma20ch	-1.49%
Net CF	-26,167,717
Next Earnings Date	2026-05-14
Open	13.72
Position In Range	36.59
Ppne	90,681,401.8
Price Date	2026-05-08
Ptbv Ratio	2.9
Relative Volume	0.89x
Revenue	50,279,553x
SBC By Revenue	118.54x
Share Based Comp	59,602,717
Tr6m	55.46%
Volume	38,624
Z Score	-1.19

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does LON/0JBU pay a dividend?

Capital-return profile for this ticker.

Performance

LON/0JBU stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns LON/0JBU?

Insider, institutional, and short-interest positioning.

Institutional ownership

+73.6%

Share of float held by funds and institutions

Insider ownership

+1.3%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

LON/0JBU momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

51.2

Neutral momentum band

Price vs 200-day MA

+6.2%

50/200-day relationship not available

Beta (5Y)

1.93

More volatile than the market

Sharpe ratio

0.99

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About LON/0JBU

Hub-level FAQ points readers to the deeper analysis pages.

What is the current lon/0JBU stock rating?

lon/0JBU is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full lon/0JBU analysis?

The full report lives at /stocks/lon/0JBU/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for lon/0JBU?

The latest report frames lon/0JBU around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the lon/0JBU page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.